14.2 Allergies, Sensitivities & Cross-Reactivity

13.2 Allergies, Sensitivities & Cross-Reactivity

Quick Answer: Treat “allergy” labels with clinical precision. Distinguish true IgE-mediated allergy from intolerance, predictable side effects, and other non-allergic reactions. For beta-lactams, avoid outdated blanket bans on all cephalosporins after any penicillin label—use reaction detail, timing, and modern cross-reactivity concepts. Clarify sulfonamide antibiotic versus non-antibiotic sulfa issues, consider excipients, document accurately, and refer to allergy specialists when history is high-risk or uncertain and first-line therapy matters.

Allergy mismanagement harms patients in two directions: re-exposing someone with true anaphylaxis risk, or withholding preferred antibiotics forever because of a vague childhood “rash” that was never allergic. Standard 3.3 monitoring includes maintaining an accurate safety profile for every patient you supply.

True IgE allergy versus intolerance versus side effect

Use history to place the reaction in a working category. Exact immunology testing is specialist territory; your job is safe triage language and documentation.

Likely IgE-mediated (immediate) drug allergy features

• Onset typically minutes to 1–2 hours after a dose (often faster with injectables)
• Urticaria, angioedema, bronchospasm/wheeze, hypotension, anaphylaxis
• May occur after previously tolerated courses (sensitisation)
• Future exposure can be dangerous; label clearly, avoid culprit, plan alternatives

Delayed hypersensitivity (not classic immediate IgE)

• Onset often hours to days (sometimes longer) into a course
• Maculopapular rashes, severe cutaneous adverse reactions (SJS/TEN), DRESS, some cytopenias
• Management still often requires avoidance of the culprit and selected related drugs; not “just a side effect”

Intolerance / sensitivity (non-immune in the IgE sense)

• Predictable discomfort without allergic mechanism—e.g. codeine nausea, erythromycin gastric upset, opioid itch without urticarial anaphylaxis picture
• May be dose-related or formulation-related
• Alternatives, dose/formulation changes, or slower titration may allow continued class use

Pharmacological side effect mislabelled as allergy

Classic traps:

• ACE inhibitor cough documented as “ACEI allergy,” leading to inappropriate avoidance of useful related therapy discussions
• Diarrhoea on antibiotics labelled as allergy without distinguishing mild effect from severe colitis
• Statin myalgia without CK crisis labelled as lifelong “statin anaphylaxis”

Mislabels block future options. When history is soft, document what happened, not only the word “allergy.”

Taking an allergy history that changes decisions

Ask structured questions:

1. Which exact medicine (and formulation if known)?
2. When (year, age, how many doses into therapy)?
3. What happened (rash type, swelling, breathing, BP, fever, blistering, organ involvement)?
4. How soon after the dose/course?
5. Treatment required (antihistamine only, adrenaline, hospital, ICU)?
6. Outcome and any later exposure to related drugs (tolerated cephalexin after penicillin label?).
7. Other allergies (foods, latex, excipients) and atopic background when relevant.

Red flags for do not rechallenge in community and seek urgent/specialist pathways: anaphylaxis features, severe cutaneous reactions, organ-threatening delayed syndromes, or unclear but serious historical events.

Penicillin–cephalosporin cross-reactivity: modern nuanced approach

Older teaching sometimes claimed ~10% cross-reactivity across all cephalosporins after any penicillin allergy, leading to blanket avoidance of the entire beta-lactam family. Contemporary practice is more nuanced:

• Many penicillin “allergy” labels are not true IgE allergy on evaluation.
• Cross-reactivity risk relates substantially to shared side chains and the specific agents involved, not a uniform property of every beta-lactam.
• First-generation cephalosporins and some agents with similar side chains historically carried more concern in penicillin-allergic patients than many later-generation cephalosporins with dissimilar structures—but you must still individualise using history and guidelines/specialist advice rather than memorising a single percentage as destiny.
• Carbapenems and monobactams (e.g. aztreonam in many contexts) have distinct cross-reactivity considerations; aztreonam is often considered in selected penicillin-allergic patients under specialist/ID guidance, with caution if ceftazidime side-chain issues are relevant.

Practical intern approach (exam-safe)

1. Clarify the penicillin reaction (immediate anaphylaxis vs delayed rash vs unknown).
2. Do not automatically chart “all beta-lactams contraindicated forever” without detail.
3. For true anaphylaxis to penicillin, do not casually supply another beta-lactam from the shelf without a documented risk assessment, guideline-supported choice, and often senior/ID/allergy input—especially in community settings without emergency backup.
4. For remote non-severe delayed rash, many guidelines support structured assessment; some patients can receive selected cephalosporins after risk stratification—this is a prescriber/specialist decision, while you prevent both reckless supply and unnecessary total restriction.
5. Prefer accurate labels: “Amoxicillin—possible delayed rash 1998; cephalexin tolerated 2024” is gold-standard clinical memory.

Bottom line for APC vignettes: Reject the outdated reflex “penicillin allergy = never any cephalosporin or carbapenem under any circumstances without thinking.” Also reject the opposite reflex “all labels are false—give anything.” History detail drives the decision.

Sulfonamide (“sulfa”) antibiotic versus non-antibiotic sulfa

Patients often say “sulfa allergy” after a reaction to trimethoprim–sulfamethoxazole or another sulfonamide antibiotic. Key teaching points:

• Cross-reactivity among sulfonamide antibiotics can be clinically relevant; treat with caution inside that group after significant reactions.
• Many medicines contain a sulfonamide moiety or sulfur but are not sulfonamide antibiotics (examples discussed in practice include some diuretics, sulfonylureas, and celecoxib-type agents). Automatic cross-allergy to all “sulfur drugs” is not evidence-based.
• Decision-making depends on reaction severity/type, the specific culprit, and clinical need—use AMH/product information and specialist advice for high-stakes cases rather than folklore charts that ban every sulfur-containing molecule.

Also distinguish sulfite preservative sensitivity (e.g. in some injectables/foods) from sulfonamide antibiotic allergy—patients confuse the words.

Excipient allergies and formulation traps

The active pharmaceutical ingredient may be fine while an excipient causes problems:

• Colouring agents or dyes in liquids/tablets
• Preservatives in multi-dose eye drops or injectables
• Peanut oil or other oils in selected products (check current formulations; products change)
• Lactose in highly sensitive rare scenarios (usually not true allergy for most “lactose intolerant” patients at tablet excipient levels, but clarify the patient’s actual problem)
• Gelatin in some capsules (relevant for certain cultural/religious preferences and rare gelatin allergy)

When a patient reports reaction to “one brand only,” compare excipients before concluding active-drug allergy. Conversely, do not dismiss brand-specific reactions without checking.

Documenting allergy status accurately

Good documentation is a patient-safety intervention:

• Record drug, reaction description, date/approx year, severity, and source (patient report, hospital discharge, observed).
• Prefer structured allergy fields plus free-text detail over a single ambiguous “+” flag.
• Update when the patient later tolerates a related drug—this is as important as recording the index reaction.
• Remove or amend incorrect labels only through a clear clinical process (often medical/allergy review), not casual deletion because the patient “needs a script today.”
• Communicate changes to the usual GP and relevant specialists; hospital–community discrepancies are a major error source at transitions of care.

When to use an alternative versus when to seek specialist allergy advice

Prefer an alternative (with clinical justification)

• Clear recent anaphylaxis to the proposed drug
• History consistent with SJS/TEN, DRESS, or other severe delayed drug hypersensitivity to that agent/class where re-exposure is unacceptable
• Equally effective, safer alternative available for a non-critical indication
• Community setting without capacity for supervised challenge

Seek allergy/immunology (or infectious diseases) advice

• Critical infection where beta-lactam is clearly superior and the allergy label is uncertain or old
• Need for delabelling, skin testing, or supervised challenge pathways
• Multiple antibiotic allergy labels causing progressive loss of options
• Severe historical reaction with incomplete detail but high stakes
• Possible dual issues (e.g. allergy plus multidrug-resistant organism limiting choices)

Pharmacists contribute by gathering history, preventing inappropriate supply, suggesting evidence-aligned alternatives at a high level, and advocating referral rather than improvising high-risk re-exposure.

Putting it together for the exam

Expect questions that test whether you:

• Misclassify ACEI cough or opioid nausea as IgE allergy
• Apply blanket beta-lactam bans without history nuance
• Confuse sulfa antibiotic allergy with all sulfur drugs or sulfites
• Fail to document reaction detail
• Supply a cephalosporin casually after recent penicillin anaphylaxis—or refuse all antibiotics forever after a vague childhood rash without seeking a better plan

Accurate allergy reasoning is core medication-safety monitoring: right restriction, right alternative, right referral, right record.